Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -69.47% is 63% below its 5-year average of -42.58%, near the low end of its 5-year range (-75.07%–-16.25%).
As of the fiscal period ended Tuesday, June 30, 2026. 13.24% below its 12-month average of -61.35%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q3 FY2026 (2026-06-30): -69.47%.
RETURN ON EQUITY (ROE)
-69.47%
RETURN ON EQUITY (ROE) AVG TTM
-61.35%
RETURN ON EQUITY (ROE) AVG 3Y
-53.47%
RETURN ON EQUITY (ROE) AVG 5Y
-42.58%
RETURN ON EQUITY (ROE) AVG 10Y
-50.50%
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-13.24%
CURRENT VS 3Y AVG
-29.93%
CURRENT VS 5Y AVG
-63.16%
CURRENT VS 10Y AVG
-37.57%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-38.25%
median of 444 covered companies
CURRENT VS SECTOR MEDIAN
-81.61%
vs the sector median at left
Citius Pharmaceuticals, Inc.
Market Cap
$14.28M
Return on Equity (ROE)
-69.47%
TTM Avg
-61.35%
3Y Avg
-53.47%
5Y Avg
-42.58%
Market Cap
$13.62M
Return on Equity (ROE)
-101.66%
TTM Avg
-140.38%
3Y Avg
-131.64%
5Y Avg
-101.94%
Market Cap
$13.55M
Return on Equity (ROE)
-186.95%
TTM Avg
1198.98%
3Y Avg
241.18%
5Y Avg
112.17%
Market Cap
$15.20M
Return on Equity (ROE)
N/A
TTM Avg
54.00%
3Y Avg
301.36%
5Y Avg
162.15%
Market Cap
$15.20M
Return on Equity (ROE)
-42.72%
TTM Avg
-65.53%
3Y Avg
-58.02%
5Y Avg
-43.63%
Market Cap
$13.34M
Return on Equity (ROE)
-74.73%
TTM Avg
-265.78%
3Y Avg
-138.63%
5Y Avg
-109.18%
Market Cap
$15.30M
Return on Equity (ROE)
-951.92%
TTM Avg
-161.65%
3Y Avg
-122.41%
5Y Avg
-87.71%
Market Cap
$15.91M
Return on Equity (ROE)
-348.81%
TTM Avg
-160.92%
3Y Avg
-184.71%
5Y Avg
-151.29%
Market Cap
$12.63M
Return on Equity (ROE)
N/A
TTM Avg
-201.97%
3Y Avg
-21.23%
5Y Avg
365.72%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Citius Pharmaceuticals, Inc. (CTXR) | $14.28M | -69.47% | -61.35% | -53.47% | -42.58% |
| IN8bio, Inc. (INAB)vs › | $13.62M | -101.66% | -140.38% | -131.64% | -101.94% |
| Vyome Holdings, Inc. (HIND)vs › | $13.55M | -186.95% | 1198.98% | 241.18% | 112.17% |
| Karyopharm Therapeutics Inc. (KPTI)vs › | $15.20M | N/A | 54.00% | 301.36% | 162.15% |
| Pasithea Therapeutics Corp. (KTTA)vs › | $15.20M | -42.72% | -65.53% | -58.02% | -43.63% |
| Cellectar Biosciences, Inc. (CLRB)vs › | $13.34M | -74.73% | -265.78% | -138.63% | -109.18% |
| Cocrystal Pharma, Inc. (COCP)vs › | $15.30M | -951.92% | -161.65% | -122.41% | -87.71% |
| Allarity Therapeutics, Inc. (ALLR)vs › | $15.91M | -348.81% | -160.92% | -184.71% | -151.29% |
| Dare Bioscience, Inc. (DARE)vs › | $12.63M | N/A | -201.97% | -21.23% | 365.72% |
| Cytosorbents Corporation (CTSO)vs › | $12.46M | N/A | -162.71% | -135.96% | -98.83% |
ROE
-69.5%
ROA
-32.5%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -69.47% |
| 2026-03-31 | -75.07% |
| 2025-12-31 | -44.88% |
| 2025-09-30 | -55.42% |
| 2025-06-30 | -61.89% |
| 2025-03-31 | -69.32% |
| 2024-12-31 | -60.66% |
| 2024-09-30 | -55.85% |
| 2024-06-30 | -44.69% |
| 2024-03-31 | -45.61% |
| 2023-12-31 | -45.06% |
| 2023-09-30 | -35.83% |
| 2023-06-30 | -31.31% |
| 2023-03-31 | -33.96% |
| 2022-12-31 | -27.89% |
| 2022-09-30 | -32.72% |
| 2022-06-30 | -27.90% |
| 2022-03-31 | -23.45% |
| 2021-12-31 | -19.47% |
| 2021-09-30 | -17.44% |
| 2021-06-30 | -16.25% |
| 2021-03-31 | -16.83% |
| 2020-12-31 | -84.81% |
| 2020-09-30 | -52.12% |
| 2020-06-30 | -59.42% |
| 2020-03-31 | -74.87% |
| 2019-12-31 | -78.57% |
| 2019-09-30 | -63.84% |
| 2019-06-30 | -68.62% |
| 2019-03-31 | -59.28% |
| 2018-12-31 | -54.45% |
| 2018-09-30 | -44.99% |
| 2018-06-30 | -58.85% |
| 2018-03-31 | -55.88% |
| 2017-12-31 | -44.30% |
| 2017-09-30 | -47.32% |
| 2017-06-30 | -85.66% |
| 2017-03-31 | -79.51% |
| 2016-12-31 | -61.01% |
| 2016-09-30 | -49.48% |
| 2016-06-30 | -36.42% |
| 2016-03-31 | -18.72% |
